KBC Securities - ArGEN-X SE (ARGX) ... Morning Notes : ARGX BB, HYL BB

Report

KBC Securities

Hilde Van Boxstael ...

Thomas Couvreur
Thomas Vranken

Morning Notes : ARGX BB, HYL BB

: ARGX BB, HYL BB

19/08/2024 1 EN

Underlyings

ArGEN-X SE

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

See profile

NL0010832176 Euronext Brussels Netherlands

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Thomas Couvreur

Thomas Vranken

Other Reports on these Companies

GlobeNewsWire

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology co...

September 19, 2024 September 19, 2024 1 EN

KBC Securities

Morning Notes : HYL BB, IBAB BB, PROX BB

: HYL BB, IBAB BB, PROX BB

September 16, 2024 September 16, 2024 1 EN

SmartInsider

Argen X SE: 1 director

A director at Argen X SE sold 924 shares at 495.250EUR and the significance rating of the trade was 84/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board membe...

Free Trial

September 11, 2024 September 11, 2024 1 EN

VGP EPRA property tour to Berlin Ludwigsfelde

We visited Lidl and Zalando warehouse on the VGP Berlin park Ludwigsfelde (216k sqm). These are standard buildings of 12m high and 7 ton floor. Interestingly, there is a lot of manual labour, with an estimated 80% of labour coming out of Poland. The Polish border is 100km away and workers stay the week nearby in local housing to go back home for the weekend. The Ludwigsfelde site is about 20km out of Berlin on the A10, a big industrial artery (Tesla, etc…). VGP bought the land in 2014 and is still developing land there. See map of the VGP Berlin park below. Most tenants appear e-commerce rela...

4h / 23m 4h / 23m 1 EN

Jacob Mekhael

Jacob Mekhael

MaaT Pharma 1H24 update extends runway into 2Q25, MaaT013 phase 3 topline in 4Q24

MaaT reported 1H24 results, which come with an extension of the company's cash runway into 2Q25 (from 1Q25) through prioritisation of resources on the key programs for MaaT013 and MaaT033, while management confirmed they are exploring all options for additional funding. In addition, the company reiterates the timeline for the topline results from the phase 3 (ARES) trial of MaaT013 in aGvHD in Europe, which continue to be expected in mid-4Q24 – we view this as an important trigger for the company with a high probability of success based on the solid phase 2 results and early access program dat...

4h / 34m 4h / 34m 1 EN

Guy Sips ... (+5)

Guy Sips
Hilde Van Boxstael
Jacob Mekhael
Michiel Declercq
Wim Lewi

Morning Notes : BARb BB, OPTI BB, GIMBb BB, VGP BB, MAAT FP

: BARb BB, OPTI BB, GIMBb BB, VGP BB, MAAT FP

4h / 36m 4h / 36m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : ARGX BB, HYL BB

We are a financial services provider for several types of professional clients, each with distinct needs.

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Morning Notes : HYL BB, IBAB BB, PROX BB

Argen X SE: 1 director

VGP EPRA property tour to Berlin Ludwigsfelde

MaaT Pharma 1H24 update extends runway into 2Q25, MaaT013 phase 3 topline in 4Q24

Morning Notes : BARb BB, OPTI BB, GIMBb BB, VGP BB, MAAT FP

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe